GenomeDx Biosciences Corp   Report issue

For profit Phase 2
Founded: Vancouver BC Canada (2008)
Status: No NME R&D (2008)

Organization Overview

First Clinical Trial
2019
NCT04025372
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

GenomeDx Biosciences Corp

Active Ingredients

Drugs in Phase 2 Trials (2)

bicalutamide (casodex) (1 trial)

darolutamide (Nubeqa) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2